Pancreatic Cancer Research

ResearcherTongji UniversityActive in the last 2 years

Sen Yang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2321-3899; OpenAlex author ID A5072998478, A5120313509, A5140787722. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 9

  1. Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer. Co-author DOI 10.1136/gutjnl-2025-336117↗
  2. Comparative spatial transcriptomics of pancreatic cancer with ductal and acinar origins in mouse models. Co-author DOI 10.1002/ctm2.70416↗
  3. Pancreatic cancer cells escape T/NK cell immune surveillance through the expressional separation of CD58. Co-author DOI 10.1136/jitc-2025-012163↗
  4. Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment. Co-author DOI 10.1016/j.canlet.2024.217289↗
  5. GREM1 is a novel serum diagnostic marker and potential therapeutic target for pancreatic ductal adenocarcinoma. Co-author DOI 10.3389/fonc.2022.968610↗
  6. Dopamine improves chemotherapeutic efficacy for pancreatic cancer by regulating macrophage-derived inflammations. Co-author DOI 10.1007/s00262-020-02816-0↗
  7. Knockdown of LRRN1 inhibits malignant phenotypes through the regulation of HIF-1α/Notch pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.omto.2021.08.012↗
  8. Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming. Co-author DOI 10.3389/fcell.2020.607209↗
  9. Using the Risk Factors of Pancreatic Cancer and Their Interactions in Cancer Screening: A Case-Control Study in Shanghai, China. Co-author DOI 10.5334/aogh.2463↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qiaofei Liu · 5 shared papers, 2020–2025 · strength 0.98
  2. Ming Cui · 5 shared papers, 2021–2026 · strength 0.94
  3. Quan Liao · 5 shared papers, 2020–2025 · strength 0.92
  4. Yalu Zhang · 5 shared papers, 2021–2025 · strength 0.90
  5. Ronghua Zhang · 3 shared papers, 2021–2025 · strength 0.55
  6. Junyi Gao · 3 shared papers, 2021–2024 · strength 0.46
  7. Jorg H. Kleeff · 2 shared papers, 2024–2025 · strength 0.43
  8. Quan Liao · 2 shared papers, 2024–2025 · strength 0.41
  9. Tong Li · 2 shared papers, 2021–2024 · strength 0.29
  10. Joseph R. Habib · 1 shared paper, 2026 · strength 0.26
  11. Christopher L. Wolfgang · 1 shared paper, 2026 · strength 0.26
  12. Yu-Pei Zhao · 1 shared paper, 2026 · strength 0.26
  13. Ammar A. Javed · 1 shared paper, 2026 · strength 0.26
  14. Huaijin Zheng · 1 shared paper, 2025 · strength 0.26
  15. Jin Peng He · 1 shared paper, 2025 · strength 0.23
  16. Kevin C. Soares · 1 shared paper, 2025 · strength 0.23
  17. Yupei Zhao · 1 shared paper, 2025 · strength 0.23
  18. Lei You · 1 shared paper, 2025 · strength 0.23
  19. Junya Peng · 1 shared paper, 2024 · strength 0.18
  20. Mengyi Wang · 1 shared paper, 2022 · strength 0.16
  21. Xiang Zhang · 1 shared paper, 2021 · strength 0.12
  22. Qiaofei Liu · 1 shared paper, 2021 · strength 0.12
  23. Huanwen Wu · 1 shared paper, 2021 · strength 0.12
  24. Jingkai Liu · 1 shared paper, 2021 · strength 0.12
  25. Xiaojie Bo · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.